PCI Biotech strengthens the management team
PCI Biotech, Photocure's cancer-focused drug delivery subsidiary, strenghtens the management team and hires Per Walday as CEO.
Mr Per Walday has been appointed as new CEO of PCI Biotech starting in the second quarter of 2008. Mr Anders Høgset, current CEO will take the position as Chief Scientific Officer upon Mr Walday taking up his new position.
Mr Walday brings to PCI Biotech more than 20 years of senior management experience in the pharmaceutical sector. Mr Walday currrently holds the position as Global Head of Project Management at GE Healthcare. In this position he has been responsible for project management of all pharmaceutical development. Mr Walday brings deep insight and long experience in pharmaceutical development, ranging from preclinical research to registration and commercialization of new products. He has an extensive international network and a thorough understanding of critical success factors in drug development. Mr Walday holds a PhD from the Institute of Biology at the University of Oslo.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Needle_aspiration_biopsy
Anti-actin_antibodies
Xceleron scientific advisory board expanded
Food from CO2 - Arkeon Biotechnologies, a Viennese startup, uses gas fermentation technology to convert CO2 into food products
Emerging gene editing approach seeks broad spectrum crop disease resistance
New biologically derived metal-organic framework mimics DNA
Scientists identify rare gene variants which confer up to 6-fold increase in risk of obesity - Genetic variants reveal new biological mechanism regulating appetite control
Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing
Applied Analytics, Inc. - Burlington, USA
